Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 44Other hematologic neoplasm 5Lymphoid 5

Conditions

Hematologic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × isatuximab × Other hematologic neoplasm × Clear all
NCT05873205 2026-04-02

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
12 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT06860269 2026-02-10

GRAALL-2024

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Recruiting
1,200 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06648889 2026-01-15

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Goethe University

Phase 2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06517017 2025-11-28

UltraFrailMM

University of Utah

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT05284032 2024-07-31

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

University of Virginia

Phase EARLY_PHASE1 Terminated
3 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡